The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology
- PMID: 27862883
- PMCID: PMC5363228
- DOI: 10.1111/ajt.14107
The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology
Abstract
The XIII Banff meeting, held in conjunction the Canadian Society of Transplantation in Vancouver, Canada, reviewed the clinical impact of updates of C4d-negative antibody-mediated rejection (ABMR) from the 2013 meeting, reports from active Banff Working Groups, the relationships of donor-specific antibody tests (anti-HLA and non-HLA) with transplant histopathology, and questions of molecular transplant diagnostics. The use of transcriptome gene sets, their resultant diagnostic classifiers, or common key genes to supplement the diagnosis and classification of rejection requires further consensus agreement and validation in biopsies. Newly introduced concepts include the i-IFTA score, comprising inflammation within areas of fibrosis and atrophy and acceptance of transplant arteriolopathy within the descriptions of chronic active T cell-mediated rejection (TCMR) or chronic ABMR. The pattern of mixed TCMR and ABMR was increasingly recognized. This report also includes improved definitions of TCMR and ABMR in pancreas transplants with specification of vascular lesions and prospects for defining a vascularized composite allograft rejection classification. The goal of the Banff process is ongoing integration of advances in histologic, serologic, and molecular diagnostic techniques to produce a consensus-based reporting system that offers precise composite scores, accurate routine diagnostics, and applicability to next-generation clinical trials.
Keywords: clinical research/practice; kidney transplantation/nephrology; organ transplantation in general; pathology/histopathology; rejection; rejection: T cell mediated (TCMR); rejection: antibody-mediated (ABMR); rejection: subclinical; translational research/science.
© 2016 The Authors. American Journal of Transplantation published by Wiley Periodicals, Inc. on behalf of American Society of Transplant Surgeons.
Figures

Similar articles
-
The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials.Am J Transplant. 2018 Feb;18(2):293-307. doi: 10.1111/ajt.14625. Epub 2018 Jan 21. Am J Transplant. 2018. PMID: 29243394 Free PMC article.
-
Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions.Am J Transplant. 2014 Feb;14(2):272-83. doi: 10.1111/ajt.12590. Am J Transplant. 2014. PMID: 24472190
-
An updated Banff schema for diagnosis of antibody-mediated rejection in renal allografts.Curr Opin Organ Transplant. 2014 Jun;19(3):315-22. doi: 10.1097/MOT.0000000000000072. Curr Opin Organ Transplant. 2014. PMID: 24811440 Review.
-
Banff 2011 Meeting report: new concepts in antibody-mediated rejection.Am J Transplant. 2012 Mar;12(3):563-70. doi: 10.1111/j.1600-6143.2011.03926.x. Epub 2012 Feb 2. Am J Transplant. 2012. PMID: 22300494 Free PMC article.
-
Evolving criteria for the diagnosis of antibody-mediated rejection in renal allografts.Curr Opin Nephrol Hypertens. 2018 May;27(3):137-143. doi: 10.1097/MNH.0000000000000398. Curr Opin Nephrol Hypertens. 2018. PMID: 29300203 Review.
Cited by
-
Urine CXCL10 as a biomarker in kidney transplantation.Curr Opin Organ Transplant. 2024 Apr 1;29(2):138-143. doi: 10.1097/MOT.0000000000001135. Epub 2024 Jan 19. Curr Opin Organ Transplant. 2024. PMID: 38235748 Free PMC article. Review.
-
Assessment of chronic allograft injury in renal transplantation using diffusional kurtosis imaging.BMC Med Imaging. 2021 Apr 7;21(1):63. doi: 10.1186/s12880-021-00595-3. BMC Med Imaging. 2021. PMID: 33827457 Free PMC article.
-
Effects of immunotherapy induction on outcome and graft survival of kidney-transplanted patients with different immunological risk of rejection.BMC Nephrol. 2019 Aug 13;20(1):314. doi: 10.1186/s12882-019-1497-5. BMC Nephrol. 2019. PMID: 31409321 Free PMC article.
-
Banff Classification from 1991 to 2019. A Significant Contribution to Our Understanding and Reporting of Allograft Renal Biopsies.Indian J Nephrol. 2022 Jan-Feb;32(1):1-7. doi: 10.4103/ijn.IJN_270_20. Epub 2022 Jan 5. Indian J Nephrol. 2022. PMID: 35283563 Free PMC article. Review.
-
The Role of Major Histocompatibility Complex in Organ Transplantation- Donor Specific Anti-Major Histocompatibility Complex Antibodies Analysis Goes to the Next Stage.Int J Mol Sci. 2019 Sep 13;20(18):4544. doi: 10.3390/ijms20184544. Int J Mol Sci. 2019. PMID: 31540289 Free PMC article. Review.
References
-
- Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: Inclusion of c4d‐negative antibody‐mediated rejection and antibody‐associated arterial lesions. Am J Transplant 2014; 14: 272–283. - PubMed
-
- Sis B, Mengel M, Haas M, et al. Banff ‘09 meeting report: Antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10: 464–471. - PubMed
-
- Mengel M, Chan S, Climenhaga J, et al. Banff initiative for quality assurance in transplantation (BIFQUIT): Reproducibility of C4d immunohistochemistry in kidney allografts. Am J Transplant 2013; 13: 1235–1245. - PubMed
-
- Farris AB, Chan S, Climenhaga J, et al. Banff fibrosis study: Multicenter visual assessment and computerized analysis of interstitial fibrosis in kidney biopsies. Am J Transplant 2014; 14: 897–907. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials